Cosentyx is a biologic drug that is used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. Like any medication, it may cause side effects, including the risk of developing infections. According to the Cosentyx website [3], patients taking Cosentyx are at an increased risk of developing infections, including serious infections such as tuberculosis (TB), sepsis, and opportunistic infections. The website advises patients to seek medical attention immediately if they experience symptoms of an infection, such as fever, cough, or flu-like symptoms.

A study published in the Arthritis Research & Therapy Journal [2] found that patients taking Cosentyx had a higher incidence of infections than those taking a placebo. The study also found that the types of infections reported were similar to those reported in previous studies of other biologic drugs. The most common infections reported were upper respiratory tract infections, urinary tract infections, and gastroenteritis. The study concluded that patients taking Cosentyx should be monitored for signs of infection and that appropriate measures should be taken to manage infections promptly.

Drug Patent Watch [1] lists the adverse events associated with Cosentyx, including the risk of infections. The website reports that clinical trials have shown that Cosentyx can increase the risk of infections, including serious infections. The website advises patients to inform their healthcare provider if they have a history of infections or if they are taking medications that suppress their immune system.

In conclusion, Cosentyx is associated with an increased risk of infections, including serious infections such as TB, sepsis, and opportunistic infections. Patients taking Cosentyx should be monitored for signs of infection and should seek medical attention immediately if they experience symptoms of an infection. It is important for patients to inform their healthcare provider if they have a history of infections or if they are taking medications that suppress their immune system.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1882-2
[3] https://info.cosentyx.com/plaque-psoriasis/safety